Iongen Therapeutics Co., Ltd. ("Iongen Therapeutics"), a biotechnology company developing best-in-class non-opioid pain medicines, announced the successful completion of its Pre-A financing round, raising over 100 million RMB. The round was led by Qiming Venture Partners. The investment will support the company's preclinical and early clinical development of its management portfolio, with a focus on accelerating the development of novel Nav1.8 sodium channel-targeting small-molecule drug.
"Our team has long been dedicated to fundamental research on ion channels," said Professor Lei Xiaoguang, Co-Founder of Iongen Therapeutics. "By positioning Iongen Therapeutics as a specialized ion channel drug development platform, we aim to accelerate the development of novel pain therapies and benefit millions of patients worldwide. We are grateful for the unwavering confidence investors have in our assets and platform, and confident that this round will accelerate a smooth and successful execution of our pipeline."
Dr. Chen Kan, Partner and Co-Lead of Healthcare at Qiming Venture Partners, added, "We are impressed by Iongen Therapeutics' innovative approach and scientific expertise in ion channel-targeted drug development. We believe the company's strong R&D capabilities will lead to breakthrough therapies, bringing hope and relief to the growing global population of patients suffering from pain."
The round was led by Qiming Venture Partners and joined by Insight Capital and Tsinghua Holdings Ginkgo.
